

Javier De Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4130229/publications.pdf>

Version: 2024-02-01

106
papers

8,548
citations

236925

25
h-index

58581

82
g-index

114
all docs

114
docs citations

114
times ranked

9503
citing authors

#	ARTICLE	IF	CITATIONS
1	Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. <i>Oncology and Therapy</i> , 2022, 10, 167-184.	2.6	12
2	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 2924-2933.	1.6	127
3	Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. <i>Oncotarget</i> , 2022, 13, 812-827.	1.8	2
4	An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8600-TPS8600.	1.6	1
5	Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 8542-8542.	1.6	0
6	Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 8501-8501.	1.6	41
7	Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1185-1192.	2.4	12
8	Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK+ advanced tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 475-486.	2.3	6
9	Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. <i>ESMO Open</i> , 2021, 6, 100045.	4.5	18
10	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	1.6	317
11	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	329
12	Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay. <i>Oncologist</i> , 2021, 26, e908-e912.	3.7	6
13	Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting. <i>Journal of Clinical Oncology</i> , 2021, 39, e21112-e21112.	1.6	0
14	Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase. <i>Journal of Clinical Oncology</i> , 2021, 39, 8567-8567.	1.6	0
15	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	4.0	26
16	Abstract 560: High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial. , 2021, , .		0
17	Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study. <i>Frontiers in Oncology</i> , 2021, 11, 695038.	2.8	3
18	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. <i>Future Oncology</i> , 2021, 17, 4011-4025.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer. <i>Clinical Epigenetics</i> , 2021, 13, 167.	4.1	7
20	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5878-5890.	7.0	30
21	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
22	PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4583.	2.4	3
23	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	2.4	11
24	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 989-1003.	2.4	59
25	Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database. <i>Thoracic Cancer</i> , 2020, 11, 3357-3364.	1.9	18
26	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. <i>Cancers</i> , 2020, 12, 3459.	3.7	11
27	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1413-1422.	10.7	475
28	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362.	1.8	16
29	Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription. <i>Current Medical Research and Opinion</i> , 2020, 36, 1383-1391.	1.9	2
30	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	2.4	4
31	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	7.1	70
32	A Novel Role for the Tumor Suppressor Gene ITF2 in Tumorigenesis and Chemotherapy Response. <i>Cancers</i> , 2020, 12, 786.	3.7	9
33	Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for second-line treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21555-e21555.	1.6	0
34	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	10.7	247
35	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. <i>British Journal of Cancer</i> , 2019, 121, 131-138.	6.4	16
36	Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2036.	4.1	18

#	ARTICLE	IF	CITATIONS
37	Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. <i>Clinical Cancer Research</i> , 2019, 25, 64-72.	7.0	159
38	Clinical utility of plasma-based digital next-generation sequencing in patients with advanced-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296.	1.2	55
39	Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2019, 21, 534-538.	2.4	0
40	Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected. <i>Journal of Clinical Oncology</i> , 2019, 37, 2501-2501.	1.6	14
41	Carcinoma microcítico de mama con afectación pulmonar. <i>Archivos De Bronconeumología</i> , 2018, 54, 586-587.	0.8	0
42	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1156-1169.	2.4	47
43	Afectación muscular de un mesotelioma maligno pleural de larga evolución. <i>Archivos De Bronconeumología</i> , 2018, 54, 284-285.	0.8	0
44	P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S553-S554.	1.1	0
45	OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S320.	1.1	6
46	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350.	27.0	2,150
47	Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e183486.	7.1	23
48	Health care resource use among patients with advanced non-small cell lung cancer: the PivOTAL retrospective observational study. <i>BMC Health Services Research</i> , 2018, 18, 147.	2.2	15
49	Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PivOTAL observational study. <i>PLoS ONE</i> , 2018, 13, e0202865.	2.5	50
50	Abstract 4413: DNA methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. <i>Cancer Research</i> , 2018, 78, 4413-4413.	0.9	1
51	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 219-226.	2.4	3
52	Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1919-1929.	27.0	3,261
53	Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PivOTAL study. <i>European Journal of Cancer Care</i> , 2017, 26, e12734.	1.5	39
54	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. <i>European Journal of Cancer</i> , 2017, 82, 27-33.	2.8	25

#	ARTICLE	IF	CITATIONS
55	Difícil manejo en paciente con adenocarcinoma de pulmón con mutación de EGFR y enfermedad cerebral. Archivos De Bronconeumología, 2017, 53, 37-38.	0.8	0
56	P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC. Journal of Thoracic Oncology, 2017, 12, S1897.	1.1	4
57	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219.	4.5	87
58	Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2017, 35, 8509-8509.	1.6	25
59	Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).. Journal of Clinical Oncology, 2017, 35, 9004-9004.	1.6	9
60	Expression patterns for nicotinic acetylcholine receptor subunit genes in smoking-related lung cancers. Oncotarget, 2017, 8, 67878-67890.	1.8	30
61	SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016). Clinical and Translational Oncology, 2016, 18, 1237-1242.	2.4	10
62	ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology, 2016, 27, vi449.	1.2	4
63	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. Lung Cancer, 2016, 92, 35-40.	2.0	15
64	Adenoma pleomórfico pulmonar. A propósito de un caso. Archivos De Bronconeumología, 2016, 52, 50.	0.8	1
65	Ilustramos la dificultad en el diagnóstico y tratamiento del sarcoma pulmonar. Archivos De Bronconeumología, 2016, 52, 331.	0.8	0
66	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. Journal of Clinical Oncology, 2016, 34, e20522-e20522.	1.6	7
67	Next generation sequencing (NGS) as a useful tool to identify clinically meaningful somatic and germinal variants in the early stages of non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e20068-e20068.	1.6	0
68	Adverse Events Costs Associated With Erlotinib Or Afatinib In Non-Small Cell Lung Cancer (Nslc) Patients With Egfr Mutation-Positive Tumours. Value in Health, 2015, 18, A429.	0.3	3
69	Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Molecular and Clinical Oncology, 2015, 3, 725-729.	1.0	5
70	Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer, 2015, 88, 215-222.	2.0	58
71	Tumor fibroso solitario pleural maligno: una rara entidad. Archivos De Bronconeumología, 2015, 51, 362-363.	0.8	0
72	Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. Clinical Lung Cancer, 2015, 16, 431-446.	2.6	48

#	ARTICLE	IF	CITATIONS
73	Hallazgo de mutación de resistencia al gen del receptor del factor de crecimiento epidérmico: a propósito de un caso. Archivos De Bronconeumología, 2015, 51, 477-478.	0.8	1
74	Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer, 2015, 90, 427-432.	2.0	57
75	Abstract 3443: A new medical tool to discriminate on a radiotherapy concomitant treatment for non-small cell lung cancer patients. , 2015, , .		0
76	Iron deficiency in patients with solid tumours: prevalence and management in clinical practice. Clinical and Translational Oncology, 2014, 16, 823-828.	2.4	12
77	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer, 2014, 84, 161-167.	2.0	81
78	Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy. Value in Health, 2014, 17, A70.	0.3	0
79	ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with carboplatin, paclitaxel, and bevacizumab (CPB).. Journal of Clinical Oncology, 2014, 32, e19014-e19014.	1.6	1
80	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. PLoS ONE, 2014, 9, e107200.	2.5	58
81	KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. Translational Lung Cancer Research, 2013, 2, 142-51.	2.8	18
82	PCN76 Cost-Effectiveness of Erlotinib as First-Line Maintenance Therapy for Advanced Non-Small-Cell Lung Carcinoma in Patients EGFR WT and Stable Disease After Four Cycles of Chemotherapy. Value in Health, 2012, 15, A422-A423.	0.3	0
83	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clinical and Translational Oncology, 2012, 14, 338-349.	2.4	35
84	Abstract 1726: A novel biomarker panel identifies the response to CDDP treatment in NSCLC patients. , 2012, , .		0
85	Long-term survivors with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) chemotherapy (CT) plus bevacizumab (B) and maintenance (mtc) B.. Journal of Clinical Oncology, 2012, 30, e18055-e18055.	1.6	0
86	9141 POSTER Phase I/II Trial of Vorinostat (V) in Combination With Erlotinib (E) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients (pts) With EGFR Mutations After Erlotinib Progression â€” the TARZO Trial (NCT00503971). European Journal of Cancer, 2011, 47, S635-S636.	2.8	1
87	AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). European Journal of Cancer, 2011, 47, 16.	2.8	32
88	1447 POSTER First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study (FRAME). European Journal of Cancer, 2011, 47, S183.	2.8	0
89	Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVWA).. Journal of Clinical Oncology, 2011, 29, e18033-e18033.	1.6	0
90	Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patientâ€™s convenience on day 8 NVBO administration.. Journal of Clinical Oncology, 2011, 29, e18060-e18060.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases.. Journal of Clinical Oncology, 2010, 28, 3589-3589.	1.6	1
92	A combined strategy of serial analysis of gene expression (SAGE) and quantitative PCR (qPCR) to identify four genes that predict outcome in non-small cell lung cancer patients.. Journal of Clinical Oncology, 2010, 28, e17502-e17502.	1.6	0
93	2103 Accuracy of integrated PET-CT for mediastinal lymph node metastases in non-small cell lung cancer. European Journal of Cancer, Supplement, 2009, 7, 169.	2.2	1
94	Survival prediction in terminally ill cancer patients: Description and validation of a new predictive score. Journal of Clinical Oncology, 2009, 27, 9595-9595.	1.6	0
95	Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: A subgroup analysis of the NeoPrevent study. Lung Cancer, 2008, 59, 211-218.	2.0	4
96	Use of global expression profile from non-small cell lung carcinoma (NSCLC) surgical samples to predict response to pemetrexed (P). Journal of Clinical Oncology, 2008, 26, 2542-2542.	1.6	0
97	Use of Internet among cancer patients and their relatives in Spain. Journal of Clinical Oncology, 2008, 26, 20704-20704.	1.6	0
98	Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 2007, 59, 35-42.	2.3	9
99	Biweekly docetaxel (Doc) followed by gemcitabine (Gem) and cisplatin (Cis) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A clinical proteomic study. Journal of Clinical Oncology, 2007, 25, 18096-18096.	1.6	0
100	Optimising the response to epoetin beta for the treatment of cancer-related anaemia. Current Medical Research and Opinion, 2006, 22, S35-S44.	1.9	1
101	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. British Journal of Cancer, 2006, 94, 969-975.	6.4	114
102	P-836 Epoetin beta (NeoRecormon®) prevents anaemia and improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer, 2005, 49, S339.	2.0	2
103	A combination of oxaliplatin and UFT-I,-leucovorin as first line treatment in advanced colorectal cancer. An ONCOPAZ phase II study. Journal of Clinical Oncology, 2004, 22, 3726-3726.	1.6	1
104	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. Journal of Clinical Oncology, 2004, 22, 3746-3746.	1.6	1
105	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. Journal of Clinical Oncology, 2004, 22, 3746-3746.	1.6	3
106	β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 599-604.	2.8	41